Benign Prostatic Hyperplasia & Prostate Cancer Study Notes

Benign Prostatic Hyperplasia (BPH)

  • Definition & Pathophysiology: Age-related, nonmalignant enlargement of the prostate gland characterized by discrete nodular lesions in the periurethral region, causing upward extension into the bladder and urinary outflow obstruction.

  • Prevalence: Most common in men older than 60 years60\,\text{years}.

  • Risk Factors: Age, family history, ethnicity (Hispanic descent, African descent), obesity, sedentary lifestyle, and diabetes mellitus.

  • Clinical Manifestations:

    • Urinary frequency, urgency, and nocturia.

    • Hesitancy or difficulty starting the urinary stream.

    • Weak or intermittent urine stream and terminal dribbling.

    • Incomplete bladder emptying and urine retention.

Comparison of a Normal Prostate and Benign Prostatic Enlargement

BPH Management and Interventions

  • Pharmacotherapy:

    • Alpha Blockers: Relax smooth muscle fibers in the prostate and bladder neck to improve urinary flow.

    • 5-Alpha5\text{-Alpha} Reductase Inhibitors: Antiandrogen agents that prevent hormonal changes to shrink enlarged prostate tissue.

    • Phosphodiesterase-5 Inhibitors: Tadalafil (Cialis) used for combined treatment of prostate enlargement and erectile dysfunction.

  • Minimally Invasive Therapies:

    • Transurethral Microwave Thermotherapy (TUMT): Delivers microwave heat via a transurethral probe to raise tissue temperature to approximately 113 ∘F (45 ∘C)113\,^\circ\text{F}\ \left(45\,^\circ\text{C}\right), causing tissue necrosis and relieving obstruction.

    • Transurethral Needle Ablation (TUNA): Uses low-wave radiofrequency energy to generate localized prostatic necrosis.

    • Laser Prostatectomy: Uses laser energy via endoscopes for cutting, coagulation, and tissue vaporization.

  • Surgical Intervention (TURP):

    • Transurethral Resection of the Prostate (TURP): Surgical removal of inner prostate tissue using a resectoscope passed through the urethra without external incisions.

    • Postoperative Nursing Care: Maintain continuous or intermittent bladder irrigation (CBI) to keep catheter patent; observe drainage (bleeding should diminish to light pink within 24 hours24\,\text{hours}); manage bladder spasms; prevent constipation and straining using high-fiber diets and laxatives; perform Kegel exercises for incontinence; prevent DVT with sequential compression stockings and low-dose heparin.

Postoperative Nursing Care Guidelines for TURP

Prostate Cancer Risk Factors and Diagnosis

  • Epidemiology: Second most common cancer diagnosed in men and sixth leading cause of male cancer death worldwide.

  • Demographics: Median age at diagnosis is 71 years71\,\text{years} in White men and 69 years69\,\text{years} in Black men; highest incidence and mortality occur in African-American men.

  • Etiological Factors: Genetic variations influencing intestinal calcium absorption; higher per capita milk consumption correlates with increased prostate cancer mortality.

  • Diagnostic Modalities:

    • Prostate Specific Antigen (PSA): Normal baseline range is 0−4 ng/mL0-4\,\text{ng/mL}. BPH range often measures 4−8 ng/mL4-8\,\text{ng/mL}, while levels exceeding 4 ng/mL4\,\text{ng/mL} prompt biopsy and levels above 10 ng/mL10\,\text{ng/mL} strongly indicate malignancy.

    • Clinical Precaution: Blood for PSA testing must be drawn prior to performing a digital rectal examination (DRE).

    • Biopsy & Grading: Tissue biopsy evaluated using the Gleason score and ISUP Grade Groups (1−51-5) to predict prognosis.

Prostate Specific Antigen Diagnostic Reference Ranges

Staging and Classification

  • Anatomic Tumor Staging (T-Stage):

    • T1: Asymptomatic tumor discovered incidentally on histological examination.

    • T2: Palpable tumor confined entirely within the prostate gland.

    • T3: Tumor extension beyond the prostatic capsule.

    • T4: Direct invasion into adjacent organ structures.

  • Clinical Stages:

    • Stage I: Small tumor confined strictly to the prostate.

    • Stage II: Larger tumor involving one or both lobes, still localized to the prostate.

    • Stage III: Tumor spread to nearby seminal vesicles or local lymph nodes.

    • Stage IV: Metastatic disease extending to distant organs or bone.

Practice Questions

  • Question 1: A nurse is providing a program for older men in a senior community center about measures that can be taken to reduce the risk for prostate cancer. Which of the following would the nurse include in the program?

    • Decrease red meat and fat intake

    • Decrease lycopene intake

    • Increase fiber intake

    • Avoid foods high in sodium

  • Question 2: To determine the severity of the symptoms for a patient with benign prostatic hyperplasia (BPH), the nurse will ask the patient about:

    • The presence of blood in the urine

    • Any erectile dysfunction (ED)

    • Occurrence of a weak urinary stream

    • Lower back and hip pain